The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical, bioanalytical, […]

Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy. To shine […]

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven […]